专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明申请

US20230134932A1 EIF4E INHIBITORS AND USES THEREOF 有权
公开(公告)号：US20230134932A1
公开(公告)日：2023-05-04
申请号：US17822337
申请日：2022-08-25
申请人： PIC Therapeutics, Inc.
发明人： Christopher L. VANDEUSEN
IPC分类号： C07D417/14 , C07D417/12
摘要： The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof.

52. 发明申请

US20230134844A1 BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT 有权
公开(公告)号：US20230134844A1
公开(公告)日：2023-05-04
申请号：US17902374
申请日：2022-09-02
申请人： AGENEBIO, INC.
发明人： Belew Mekonnen , John A. Butera , Jianxing Huang , Hemantbhai Patel
IPC分类号： C07D487/14
摘要： This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of a α5-containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

53. 发明申请

US20230134471A1 METHOD FOR PRODUCING (METH)ACRYLOXY GROUP-CONTAINING ORGANOSILICON COMPOUNDS 有权
公开(公告)号：US20230134471A1
公开(公告)日：2023-05-04
申请号：US17963549
申请日：2022-10-11
申请人： Shin-Etsu Chemical Co., Ltd.
发明人： Takeshi NYUUGAKU
IPC分类号： C07F7/14
摘要： An acryloxy or methacryloxy group-containing organosilicon compound of the formula (wherein R1 is a substituted or unsubstituted monovalent hydrocarbon group of 1 to 10 carbon atoms, R2 is a hydrogen atom or a methyl group, R3 is an unsubstituted divalent hydrocarbon group of 1 to 18 carbon atoms, X is a halogen atom and n is an integer of 1, 2 or 3) is to prepared by subjecting a hydrohalosilane compound of the formula HSiXnR13-n (1) and an alkenyl group-containing (meth)acrylate compound of the formula to a hydrosilylation reaction in the presence of an acid amide compound and a platinum catalyst. This method is able to suppress, in the industrial scale production of (meth)acryloyloxy group-containing organosilicon compounds, propagation reactions by which the starting (meth)acrylate compound self-polymerizes.

54. 发明申请

US20230134307A1 HETEROCYCLIC NMDA ANTAGONISTS 有权
公开(公告)号：US20230134307A1
公开(公告)日：2023-05-04
申请号：US18087302
申请日：2022-12-22
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
发明人： Shuhei IKEDA , Makoto KAMATA , Yuya OGURO , Jumpei AIDA , Taisuke TAWARAISHI , Takeshi WAKABAYASHI , Norio OYABU , Atsuko OCHIDA , Kouichi IWANAGA , Satoshi YAMAMOTO , Masataka MURAKAMI , Minoru NAKAMURA , Fumie YAMAGUCHI , Takafumi YUKAWA
IPC分类号： C07D207/263 , A61P25/18 , C07D401/06
摘要： A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

55. 发明申请

US20230133996A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES 有权
公开(公告)号：US20230133996A1
公开(公告)日：2023-05-04
申请号：US18069016
申请日：2022-12-20
申请人： Universal Display Corporation
发明人： Zhiqiang JI , Lichang ZENG , Jui-Yi TSAI , Chun LIN , Chuanjun XIA , Alexey Borisovich DYATKIN , Walter YEAGER
IPC分类号： H10K85/30 , C09K11/06 , C09K11/02 , C07F15/00 , H10K85/60
摘要： New organometallic complexes having bis- or tris-heteroleptic ligands and large aspect ratio in one direction and their use in OLEDs to enhance the efficiency is disclosed.

56. 发明申请

US20230133817A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS 有权
公开(公告)号：US20230133817A1
公开(公告)日：2023-05-04
申请号：US18063173
申请日：2022-12-08
申请人： RQX Pharmaceuticals, Inc. , Genentech, Inc.
发明人： Yongsheng Chen , Peter Andrew Smith , Tuker Curran Roberts , Robert I. Higuchi , Prasuna Paraselli , Michael F.T Koehler , Jacob Bradley Schwarz , James John Crawford , Cuong Q. Ly , Emily J. Hanan , Huiyong Hu , Zhiyong Yu
IPC分类号： C07D245/04 , C07K5/02 , A61K38/06 , A61K38/07 , A61K38/08 , A61K45/06 , A61K31/496 , A61K31/546 , C07K5/087 , C07K5/103 , C07K5/11 , C07K7/06 , C07K7/08 , C07K5/113 , C07K9/00 , C07K5/117 , A61K31/395 , A61K31/431 , A61K31/407 , A61K31/43 , A61K31/4196 , A61K31/545 , C07K5/09 , A61P31/04 , A61K9/00
摘要： Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

57. 发明申请

US20230133716A1 PREPARATION METHOD FOR SEMAGLUTIDE 有权
公开(公告)号：US20230133716A1
公开(公告)日：2023-05-04
申请号：US17793601
申请日：2020-07-09
申请人： SHENZHEN JYMED TECHNOLOGY CO., LTD.
发明人： Xinyu LI , Yuqing FU , Lixiang ZHANG , Lin YAO , Wenjing LI
IPC分类号： C07K14/605
摘要： A preparation method for semaglutide. The method comprises: producing a semaglutide resin by means of a solid-phase synthesis, producing crude semaglutide by cleavage and deprotection, producing refined semaglutide by purification and freeze-drying, comprising the solid-phase synthesis of a semaglutide 1-6 peptide fragment resin, which is cleaved and purified to serve as a first peptide fragment; and synthesizing a lysine having a sidechain group at locus 20 of semaglutide to serve as a second peptide fragment. In the method, prepared is a semaglutide loci 1-6 fully protected peptide fragment, which serves as a key starting material applied in the solid-phase synthesis of semaglutide, thus reducing the generation of D-His, D-Glu, D-Thr, D-Phe racemic impurities and +Gly impurities, reducing the difficulty of coarse product purification, increasing the purity and yield of semaglutide, reducing synthesis costs, and favoring industrialized large-scale production.

58. 发明申请

US20230133715A1 CONTINUOUS CRYSTALLISATION METHOD 有权
公开(公告)号：US20230133715A1
公开(公告)日：2023-05-04
申请号：US17912646
申请日：2021-03-31
申请人： GE Healthcare AS
发明人： Torfinn Haaland , Arne Askildsen , Heidi Kvande
IPC分类号： C07C231/24 , C07C237/46
摘要： The invention provides a method of purifying 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide, comprising adding a portion of acid to a stream comprising crude 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide in a solvent and continuously crystallising the 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide from the crude 5-acetamido-N,N′-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophathalamide, with removal of at least a fraction of the solvent, wherein the crystallisation is carried out in a continuous reactor, wherein the continuous reactor is a plug flow reactor. At least three further portions of acid are added to the continuous reactor during the crystallisation.

59. 发明申请

US20230133556A1 BENZOXAZINES AND COMPOSITIONS CONTAINING THE SAME 有权
公开(公告)号：US20230133556A1
公开(公告)日：2023-05-04
申请号：US18087018
申请日：2022-12-22
申请人： CYTEC INDUSTRIES INC.
发明人： Mark Edward Harriman , Paul Mark Cross , Ram B. Gupta
IPC分类号： C08G73/02 , C08J5/18 , C08J5/24 , C08L61/34 , C08G14/06 , C08K5/357 , C07D265/16 , C08J5/04 , B29C43/00 , B29C39/00
摘要： A curable composition containing more than 80% by weight of a blend of benzoxazines, wherein the blend includes (A) one or more multifunctional benzoxazines and (B) a liquid, non-halogenated monofunctional benzoxazine. This composition has been found to be stable at high temperatures, e.g. 180° C.-250° C., and suitable for making composite materials using conventional techniques such as prepregging and liquid resin infusion.

60. 发明申请

US20230133149A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE 有权
公开(公告)号：US20230133149A1
公开(公告)日：2023-05-04
申请号：US17713284
申请日：2022-04-05
申请人： Samsung Electronics Co., Ltd.
发明人： Keisuke KORAI , Rie SAKURAI , Atsushi IMAMURA , Eigo MIYAZAKI , Wataru SOTOYAMA
IPC分类号： C07F5/02 , H01L51/00
摘要： Provided are a heterocyclic compound, an organic light-emitting device including the heterocyclic compound, and an electronic apparatus including the organic light-emitting device, the heterocyclic compound including: a group represented by Formula 1; a group represented by Formula 2; and one to four groups each independently represented by Formula 3 or 4: The substituents in Formulae 1 to 4 are the same as described in the detailed description.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式